Novartis CEO Says Planned US China Biotech Investment Limits May Hurt Drug Development
Novartis CEO Vas Narasimhan said planned U.S. restrictions on investment in Chinese biotechnology may hurt drug development.
Novartis CEO Vas Narasimhan said planned U.S. restrictions on investment in Chinese biotechnology may hurt drug development.